Affinity biosensors using recombinant native membrane proteins displayed on exosomes: Application to botulinum neurotoxin B receptor

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Desplantes, Richard ^a,b   Lévêque, Christian ^a,b   Muller, Benjamin ^c   Lotierzo, Manuela ^c   Ferracci, Géraldine ^b,d   Popoff, Michel ^e   Seagar, Michael ^a,b   Mamoun, Robert ^c   El Far, Oussama ^a,b  

^a Aix Marseille University   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIV MONTPELLIER   (France)

^d CNRS   (France)

^e INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHEMOKINE RECEPTOR CXCR4; MEMBRANE PROTEIN; POTASSIUM CHANNEL KV1.2; RECOMBINANT PROTEIN; SYNAPTOTAGMIN II;

CHEMISTRY; EXOSOME; GENETIC PROCEDURES; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

BIOSENSING TECHNIQUES; BOTULINUM TOXINS, TYPE A; EXOSOMES; KV1.2 POTASSIUM CHANNEL; MEMBRANE PROTEINS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; SYNAPTOTAGMIN II;

EID: 85018175620     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01198-1     Document Type: Article

References (43)

1. Patching, S. G. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta 1838, 43-55, doi: 10.1016/j.bbamem.2013.04.028 (2014).
2. Shen, H. H., Lithgow, T. & Martin, L. Reconstitution of membrane proteins into model membranes: seeking better ways to retain protein activities. Int J Mol Sci 14, 1589-1607, doi: 10.3390/ijms14011589 (2013).
3. Im, H. et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol 32, 490-495, doi: 10.1038/nbt.2886 (2014).
4. Zhou, Q. et al. Development of an aptasensor for electrochemical detection of exosomes. Methods 97, 88-93, doi: 10.1016/j.ymeth.2015.10.012 (2016).
5. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29, 341-345, doi: 10.1038/nbt.1807 (2011).
6. Yim, N. et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun 7, 12277, doi: 10.1038/ncomms12277 (2016).
7. Zeelenberg, I. S. et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 68, 1228-1235, doi: 10.1158/0008-5472.CAN-07-3163 (2008).
8. Hartman, Z. C. et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 29, 9361-9367, doi: 10.1016/j.vaccine.2011.09.133 (2011).
9. Peng Chen, Z. et al. Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel) 4, 1196-1222, doi: 10.3390/toxins4111196 (2012).
10. Masuyer, G., Chaddock, J. A., Foster, K. A. & Acharya, K. R. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol 54, 27-51, doi: 10.1146/annurev-pharmtox-011613-135935 (2014).
11. Rossetto, O., Megighian, A., Scorzeto, M. & Montecucco, C. Botulinum neurotoxins. Toxicon 67, 31-36, doi: 10.1016/j.toxicon.2013.01.017 (2013).
12. Nishiki, T. et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378, 253-257, doi: 10.1016/0014-5793(95)01471-3 (1996).
13. Williams, R. S., Tse, C. K., Dolly, J. O., Hambleton, P. & Melling, J. Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. European Journal of Biochemistry 131, 437-445, doi: 10.1111/ejb.1983.131.issue-2 (1983).
14. Evans, D. M. et al. Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes. European Journal of Biochemistry 154, 409-416, doi: 10.1111/ejb.1986.154.issue-2 (1986).
15. Kozaki, S., Kamata, Y., Watarai, S., Nishiki, T. & Mochida, S. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 25, 91-99, doi: 10.1006/mpat.1998.0214 (1998).
16. Ferracci, G. et al. A label-free biosensor assay for botulinum neurotoxin B in food and human serum. Anal Biochem 410, 281-288, doi: 10.1016/j.ab.2010.11.045 (2011).
17. Liu, Y. Y., Rigsby, P., Sesardic, D., Marks, J. D. & Jones, R. G. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem 425, 28-35, doi: 10.1016/j.ab.2012.02.038 (2012).
18. Leveque, C. et al. An optical biosensor assay for rapid dual detection of Botulinum neurotoxins A and E. Sci Rep 5, 17953, doi: 10.1038/srep17953 (2015).
19. De Gassart, A. et al. Exosomal sorting of the cytoplasmic domain of bovine leukemia virus TM Env protein. Cell Biol Int 33, 36-48, doi: 10.1016/j.cellbi.2008.10.001 (2009).
20. Sokolova, V. et al. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces 87, 146-150, doi: 10.1016/j.colsurfb.2011.05.013 (2011).
21. Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30, 255-289, doi: 10.1146/annurev-cellbio-101512-122326 (2014).
22. Ferracci, G., Seagar, M., Joel, C., Miquelis, R. & Leveque, C. Real time analysis of intact organelles using surface plasmon resonance. Anal Biochem 334, 367-375, doi: 10.1016/j.ab.2004.08.002 (2004).
23. Navratilova, I., Sodroski, J. & Myszka, D. G. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. Anal Biochem 339, 271-281, doi: 10.1016/j.ab.2004.12.017 (2005).
24. Berntsson, R. P., Peng, L., Dong, M. & Stenmark, P. Structure of dual receptor binding to botulinum neurotoxin B. Nat Commun 4, 2058, doi: 10.1038/ncomms3058 (2013).
25. Yao, G. et al. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol 23, 656-662, doi: 10.1038/nsmb.3245 (2016).
26. Jin, R., Rummel, A., Binz, T. & Brunger, A. T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095, doi: 10.1038/nature05387 (2006).
27. Chai, Q. et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100, doi: 10.1038/nature05411 (2006).
28. Estelles, A. et al. Exosome nanovesicles displaying G protein-coupled receptors for drug discovery. Int J Nanomedicine 2, 751-760 (2007).
29. Rasetti-Escargueil, C. et al. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B. MAbs 7, 1161-1177, doi: 10.1080/19420862.2015.1082016 (2015).
30. Dressler, D., Lange, M. & Bigalke, H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Movement disorders: official journal of the Movement Disorder Society 20, 1617-1619, doi: 10.1002/mds.20625 (2005).
31. Evans, E. R., Skipper, P. J. & Shone, C. C. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin. J Appl Microbiol 107, 1384-1391, doi: 10.1111/j.1365-2672.2009.04325.x (2009).
32. Rosen, O., Ozeri, E., Barnea, A., David, A. B. & Zichel, R. Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins. Toxins (Basel) 8, 10.3390/toxins8100276 (2016).
33. Wild, E. et al. In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics. Toxicol In Vitro 34, 97-104, doi: 10.1016/j.tiv.2016.03.011 (2016).
34. Ferracci, G., Miquelis, R., Kozaki, S., Seagar, M. & Leveque, C. Synaptic vesicle chips to assay botulinum neurotoxins. Biochem J 391, 659-666, doi: 10.1042/BJ20050855 (2005).
35. Ben David, A., Torgeman, A., Barnea, A. & Zichel, R. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate. Protein Expression and Purification 110, 122-129, doi: 10.1016/j.pep.2015.02.008 (2015).
36. Drachman, D. B., Adams, R. N., Balasubramanian, U. & Lu, Y. Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progress. Toxins (Basel) 2, 2872-2889, doi: 10.3390/toxins2122872 (2010).
37. Sakaguchi, G. Clostridium botulinum toxins. Pharmacol Ther 19, 165-194, doi: 10.1016/0163-7258(82)90061-4 (1982).
38. Couesnon, A., Molgo, J., Connan, C. & Popoff, M. R. Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine. PLoS Pathog 8, e1002583, doi: 10.1371/journal.ppat.1002583 (2012).
39. Shoji-Kasai, Y. et al. Neurotransmitter release from synaptotagmin-deficient clonal variants of PC12 cells. Science 256, 1821-1823, doi: 10.1126/science.256.5065.1820 (1992).
40. Mathupala, S. & Sloan, A. A. An agarose-based cloning-ring anchoring method for isolation of viable cell clones. Biotechniques 46, 305-307, doi: 10.2144/000113079 (2009).
41. Taylor, D. D. & Shah, S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 87, 3-10, doi: 10.1016/j.ymeth.2015.02.019 (2015).
42. Takamori, S. et al. Molecular anatomy of a trafficking organelle. Cell 127, 831-846, doi: 10.1016/j.cell.2006.10.030 (2006).
43. Marconi, S. et al. A protein chip membrane-capture assay for botulinum neurotoxin activity. Toxicol Appl Pharmacol 233, 439-446, doi: 10.1016/j.taap.2008.09.005 (2008).